Edition:
United States

miRagen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

2.65USD
18 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.65
Open
$2.76
Day's High
$2.78
Day's Low
$2.65
Volume
39,635
Avg. Vol
32,874
52-wk High
$10.68
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

miRagen Therapeutics Reports Q3 Loss Per Share $0.29
Wednesday, 7 Nov 2018 04:01pm EST 

Nov 7 (Reuters) - miRagen Therapeutics Inc ::MIRAGEN THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.29.Q3 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.$70.5 MILLION IN CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS AS OF SEPTEMBER 30, 2018.GLOBAL PHASE 2 SOLAR CLINICAL TRIAL OF COBOMARSEN IN CTCL EXPECTED TO BE INITIATED IN Q4 OF 2018.  Full Article

Miragen Announces Interim Data From Phase 1 Trial Of Cobomarsen In Mycosis Fungoides
Tuesday, 8 May 2018 04:05pm EDT 

May 8 (Reuters) - miRagen Therapeutics Inc ::MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES.MIRAGEN THERAPEUTICS INC - COBOMARSEN CONTINUED TO BE GENERALLY WELL TOLERATED AT ALL DOSE LEVELS EVALUATED.MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES.  Full Article

Miragen Therapeutics Reports Qtrly ‍loss Per Share $0.29​
Wednesday, 14 Mar 2018 04:05pm EDT 

March 14 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.MIRAGEN THERAPEUTICS INC QTRLY ‍LOSS PER SHARE $0.29​.MIRAGEN THERAPEUTICS INC - ‍INTENDS TO INITIATE A PHASE 2 CLINICAL TRIAL FOR COBOMARSEN IN PATIENTS WITH CTCL IN SECOND HALF OF 2018​.  Full Article

Miragen Therapeutics Prices Public Offering Of Common Stock
Thursday, 8 Feb 2018 06:45pm EST 

Feb 8 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS, INC. PRICES PUBLIC OFFERING OF COMMON STOCK.MIRAGEN THERAPEUTICS INC <- ‍PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 7 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.50 PER SHARE​.  Full Article

miRagen Therapeutics Announces Proposed Public Offering Of Common Stock
Monday, 5 Feb 2018 06:05am EST 

Feb 5 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 7.00 MILLION COMMON SHARES.MIRAGEN THERAPEUTICS - TO USE PROCEEDS FROM OFFERING FOR WORKING CAPITAL PURPOSES INCLUDING FUNDING OF PRODUCT CANDIDATES​' CLINICAL DEVELOPMENT.  Full Article

Miragen says MRG-106 continued to be generally well-tolerated at all dose levels
Monday, 11 Dec 2017 04:05pm EST 

Dec 11 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS INC - ANNOUNCED NEW INTERIM RESULTS FROM PHASE 1 CLINICAL TRIAL OF MRG-106 IN PATIENTS WITH MYCOSIS FUNGOIDES (MF) FORM OF CTCL.MIRAGEN THERAPEUTICS INC - MRG-106 CONTINUED TO BE GENERALLY WELL-TOLERATED AT ALL DOSE LEVELS EVALUATED AS OF DECEMBER 4, 2017.MIRAGEN THERAPEUTICS INC - INITIATED DOSING IN THREE ADDITIONAL ONCOLOGY INDICATIONS.MIRAGEN THERAPEUTICS INC - PLAN TO INITIATE A CONTROLLED PHASE 2 TRIAL IN H2 2018 TO FURTHER EVALUATE POTENTIAL OF MRG-106.  Full Article

Miragen Therapeutics reports third quarter financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Miragen Therapeutics Inc :Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 revenue $1.6 million versus $900,000.Q3 revenue view $306,000 -- Thomson Reuters I/B/E/S.Miragen Therapeutics Inc - ‍cash and cash equivalents at september 30, 2017 were $42.8 million, compared to $22.1 million at December 31, 2016​.Miragen Therapeutics Inc - qtrly ‍net loss per share, basic and diluted $0.27​.  Full Article

Miragen Therapeutics Q2 loss per share $0.34
Friday, 11 Aug 2017 04:05pm EDT 

Aug 11 (Reuters) - Miragen Therapeutics Inc :Miragen Therapeutics reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.34.Q2 revenue $700,000 versus $1.1 million.Miragen Therapeutics Inc - expects that its current cash and cash equivalents will be sufficient to fund its operations through end of 2018.  Full Article

Miragen Therapeutics announces new data from phase 1 clinical trial evaluating MRG-106
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Miragen Therapeutics Inc ::Miragen Therapeutics presents new data from phase 1 clinical trial evaluating MRG-106 in subjects with Mycosis Fungoides.MRG-106 has been generally well-tolerated to date.Only one grade 3 adverse event, Pruritus (itchy skin), was considered potentially related to MRG-106 administration.  Full Article

miRagen Therapeutics reports Q1 revenue $500,000
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - miRagen Therapeutics Inc :miRagen Therapeutics reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.60.Q1 revenue $500,000 versus $900,000.miRagen Therapeutics Inc says MRG-106 clinical data to be presented at ASCO in June 2017.miRagen Therapeutics Inc says cash balance sufficient to fund operations through 2018.  Full Article